Patients with high-grade neuroendocrine carcinomas benefit from dual checkpoint inhibition with ipilimumab and nivolumab after single-agent checkpoint inhibition has failed. Is dual checkpoint blockade ready for prime time?
Medscape Medical News
Patients with high-grade neuroendocrine carcinomas benefit from dual checkpoint inhibition with ipilimumab and nivolumab after single-agent checkpoint inhibition has failed. Is dual checkpoint blockade ready for prime time?
Medscape Medical News
